Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder
- Thursday, December 23, 2021, 7:14
- Environment
- Add a comment
SAN DIEGO, Dec. 23, 2021 /PRNewswire/ — Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the receipt of correspondence from the U.S….
About the Author
adminasapcorp has written 41555 stories on this site.